The Association between Estrogen and Progesterone Receptors Expression with the Stages of Endometrioid-type Ovarian Carcinoma at Sanglah General Hospital, Bali, Indonesia: A Preliminary Study

I Gusti Ayu Sri Mahendra Dewi; Ni Putu Ekawati

doi:10.3889/oamjms.2020.3097

Authors

I Gusti Ayu Sri Mahendra Dewi Department of Pathology Anatomy, Faculty of Medicine, Udayana University, Sanglah General Hospital, Bali, Indonesia
Ni Putu Ekawati Department of Pathology Anatomy, Faculty of Medicine, Udayana University, Sanglah General Hospital, Bali, Indonesia

DOI:

https://doi.org/10.3889/oamjms.2020.3097

Keywords:

estrogen receptor, progesterone receptor, grade, tumor size, ovarian carcinoma, endometrioid

Abstract

BACKGROUND: Ovarian cancer is the most common cause of death among gynecologic malignancies. Poor prognosis is mainly due to the high incidence of advanced stage at the time of diagnosis as well as low estrogen receptor (ER) and progesterone receptor (PR) expression. Based on it, further understanding is needed to predict the course of disease.

AIM: This study aims to evaluate the expression of ER and PR with the stages of endometrioid-type ovarian carcinoma as the more frequent type carcinoma at Sanglah General Hospital, Bali.

METHODS: An analytical cross-sectional study was conducted among 36 samples of endometrioid-type ovarian carcinoma examined at Anatomical Pathology Laboratory, Faculty of Medicine, Udayana University/Sanglah General Hospital, Denpasar. The histopathological diagnosis, grade, and tumor size, as well as determination on hematoxylin-eosin staining were assessed. The expression of ER and PR was examined using immunohistochemical stain. Data were analyzed using the SPSS version 15 software for risk analysis and p < 0.05 was assumed statistically significant.

RESULTS: Most of the samples were from 41 to 50 years of age group (41.7%) and the average age was 51.1 Â± 9.80 years old. Based on the degree of differentiation, Grade 2 was the most common cases (38.9%). However, the tumor size assessment revealed that T3 was predominant (41.7%). Positive ER and PR expressions were obtained in 18 samples (50.0%) and 14 samples (38.9%), respectively. Fisherâ€™s exact test showed a significant association between ER expression with grade (odds ratio [OR]: 6.25; 95% confidence interval [CI] 1.327â€“29.432; p = 0.018) and tumor size (OR: 4.375; 95% CI 1.027â€“18.629; p = 0.043). A similar findings also found in PR expression with grade (OR: 15.60; 95% CI 1.728â€“140.829; p = 0.004) and tumor size (OR: 6.12; 95% CI 1.394â€“26.876; p = 0.016).

CONCLUSION: ER and PR expressions are significantly associated with grade and tumor size in the endometrioid-type ovarian carcinoma.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Plum Analytics Artifact Widget Block

References

Reid BM, Permuth JB, Sellers TA. Epidemiology of ovarian cancer: A review. Cancer Biol Med. 2017;14(1):9-32. https://doi.org/10.20892/j.issn.2095-3941.2016.0084 PMid:28443200

Halon A, Materna V, Drag-Zalesinska M, Nowak-Markwitz E, Gansukh T, Donizy P, et al. Estrogen receptor alpha expression in ovarian cancer predicts longer overall survival. Pathol Oncol Res. 2011;17(3):511-8. https://doi.org/10.1007/s12253-010-9340-0 PMid:21207255

Chen S, Dai X, Gao Y, Shen F, Ding J, Chen Q. The positivity of estrogen receptor and progesterone receptor may not be associated with metastasis and recurrence in epithelial ovarian cancer. Sci Rep. 2017;7(1):16922. https://doi.org/10.1038/s41598-017-17265-6 PMid:29208958

Diep CH, Daniel AR, Mauro LJ, Knutson TP, Lange CA. Progesterone action in breast, uterine, and ovarian cancers. J Mol Endocrinol. 2015;54(2):R31-53. https://doi.org/10.1530/JME-14-0252 PMid: 25587053

Prabawa IPY, Bhargah A, Liwang F, Tandio DA, Tandio AL, Lestari AAW, et al. Pretreatment neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte Ratio (PLR) as a predictive value of hematological markers in cervical cancer. Asian Pac J Cancer Prev. 2019;20(3):863-8. https://doi.org/10.31557/APJCP.2019.20.3.863 PMid:30912405

Lenhard M, Tereza L, Heublein S, Ditsch N, Himsl I, Mayr D, et al. Steroid hormone receptor expression in ovarian cancer: Progesterone receptor B as prognostic marker for patient survival. BMC Cancer. 2012;12:553. https://doi.org/10.1186/1471-2407-12-553 PMid:23176303

Stewart CJ, Brennan BA, Chan T, Netreba J. WT1 expression in endometrioid ovarian carcinoma with and without associated endometriosis. Pathology. 2008;40(6):592-9. https://doi.org/10.1080/00313020802320697 PMid:18752126

Kumar V, Abbas AK, Aster JC. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Philadelphia (PA): Elsevier; 2015. p. 1094-5.

Burges A, Schmalfeldt B. Ovarian cancer: Diagnosis and treatment. Dtsch Arztebl Int. 2011;108(38):635-41. https://doi.org/10.3238/arztebl.2011.0635 PMid:22025930

Kurman JR, Carcangiu ML, Herrington CS, Young RH. WHO Classification of Tumor of Female Reproductive Organs. 4th ed. Lyon: International Agency for Research on Cancer (IARC); 2014. p. 17-83.

Sieh W, KÃ¶bel M, Longacre TA, Bowtell DD, deFazio A, Goodman MT, et al. Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study. Lancet Oncol. 2013;14(9):853-62. https://doi.org/10.1016/S1470-2045(13)70253-5 PMid:23845225

Cho KR, Shih IeM. Ovarian cancer. Annu Rev Pathol. 2009;4:287-313. https://doi.org/10.1146/annurev.pathol.4.110807.092246 PMid:18842102

George A, McLachlan J, Tunariu N, Della Pepa C, Migali C, Gore M, et al. The role of hormonal therapy in patients with relapsed high-grade ovarian carcinoma: A retrospective series of tamoxifen and letrozole. BMC Cancer. 2017;17(1):456. https://doi.org/10.1186/s12885-017-3440-0 PMid:28666422